FITdb, a one-stop shop for immune functional genomics so you can query, browse, and analyze your favorite genes and pathways across multiple contexts in mouse and human immune cells. #immunefunction visit fitdb.lji.org

FITdb, an Integrated Functional Immunogenomics and Transcriptomics Database

Genetic screens in immune cells enable the systematic interrogation of gene function at scale, uncovering key regulators of cell functions such as tumor cell killing and persistence. However, existing...

biorxiv.org

Japan has now joined Horizon Europe. Japan’s researchers can now partner with teams across the EU. Together, we will advance global research in health, digital technologies, and climate neutrality ↓ link.europa.eu/YP7MtB

I have been thinking since yesterday about why I find the 1% thing so, so disturbing. It's a visceral reaction of 'just no', which goes beyond the general yuck towards the enshittification of/via AI. I have finally put my finger on it: it is the feeling you get when

“the academic community is enormously heterogeneous and it’s almost impossible to keep everyone happy” Never a truer word said in this analysis of downstream consequences of openness by @jacoates.bsky.social ripplingideas.org/2026/06/26/t...

The 1% club and the rocky road ahead for bioRxiv

The recent launch of qed’s “top 1%” preprint ranking has sparked controversy, with concerns about its arbitrary nature, potential harm to authors, and low-quality inclusions. Whil…

ripplingideas.org

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://nej.md/4nWaxvM #ASCO26

Regarding ELNs, after all these years I still wish Findingsapp by @cparnot.bsky.social got resurrected. Benchling is fine, but Findings was such a joy to work with. Maybe in the age of LLMs it would be feasible to do that, add an optional web interface and collaboration features

Findings has been discontinued and will no longer be developed 😥

Dear Findings user, We have some sad news to share with you today. More than 10 years ago we set out to make the lab notebook app we would have loved to have when we were still in the lab. The result ...

community.findingsapp.com

The number of cancer deaths worldwide has more than doubled since the 1980s. Does that mean we're losing the fight against cancer? Not necessarily, because it depends on how you measure it. On this chart, you can see three ways to look at the same data. 🧵

A new tool from Rockefeller's @danmucida.bsky.social and @czbiohub.bsky.social allows scientists to closely follow newly activated T cells as they travel and change during an infection—it may inform future therapies for infection, cancer, and autoimmunity. 🔗: https://bit.ly/3NjZEWD

@ostendorflab.org, @immushuang.bsky.social, @sohailtavazoie.bsky.social et al. show that activation of LXRs elicits a T cell "pre-effector" state that enhances priming and promotes anti-tumor immunity. rupress.org/jem/article/... #TumorImmunology

Delighted to share our new paper on LXR agonism pre-conditioning T cells to more readily adopt effector states, out in @jem.org today. This was a long project started in @sohailtavazoie.bsky.social's lab and completed across the atlantic here in Berlin at Charité.

Liver-X-receptor agonism enhances T cell priming and activation to promote anti-tumor immunity

Ostendorf et al. show that activation of liver-X-receptors preconditions T cells to render them more receptive to adopting effector states upon activation.

doi.org

📣 We’re hiring! Pls share! Join my lab to study human antigen-specific B cells across vaccination & infection backgrounds & explore their plasticity. Passionate about B cells, cutting-edge immunology, molecular biology & bioinformatics? 📄Details & apply: karriere.charite.de/stellenangeb... ⏳ Feb 28

Wissenschaftliche Mitarbeiterin/ Wissenschaftlicher Mitarbeiter (d/w/m) /DoktorandIn

Teilzeit | 28.02.2026 | Campus Virchow-Klinikum, Wedding

karriere.charite.de

“We found that using AI assistance led to a statistically significant decrease in mastery.” Props to Anthropic for studying the effects of their creation and reporting results that are not probably what they wished for www.anthropic.com/research/AI-...

How AI assistance impacts the formation of coding skills

Anthropic is an AI safety and research company that's working to build reliable, interpretable, and steerable AI systems.

anthropic.com

A fascinating finding on the therapeutic potential of targeting non-coding regions of MYC!

Xuebing Wu@xuebingwu.bsky.social · 6mo ago

Does the noncoding genome actually carry more genetic information than coding seqs? Motivated by this question we mutated every bp in the 10kb MYC locus. Results are even more exciting: Decoding the MYC locus reveals a druggable ultraconserved RNA element www.biorxiv.org/content/10.6...

New post! There was a lot of innovation in medicine and biomedical research this year, and I've tried to summarize the biggest ones in this blogpost. Medical breakthroughs in 2025. Plus a serious note at the end. www.scientificdiscovery.dev/p/medical-br...

Medical breakthroughs in 2025

... and a happy new year.

scientificdiscovery.dev

Completely agree! Now I mainly wish for Prism and Flowjo replacements...

David A Knowles@davidaknowles.bsky.social · 9mo ago

I'm a longtime fan of Affinity Designer as an affordable Illustrator-killer for figures, and... it's now free?! www.canva.com/newsroom/new... Highly recommended if you're sick of paying Adobe $. Maybe Canva can buy NPG too and get rid of the OA fees.

Friday Papers Club! 🍿In light of Pubmed going down, the collapse of social media, and my recent success at getting recommendations for interesting papers from those still around, I am starting a new tradition! - Recommend a good scientific manuscript! 👇

For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper? You got it: currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...

Doomscrolling pause to chat CRISPR libraries! Preprint describes our new, data-driven approach to combine on-target and off-target predictions much more intelligently for *selecting* guides, which we use to develop our newest Cas9 knockout library, Jacquere. Thread: www.biorxiv.org/content/10.1...

Balancing off-target and on-target considerations for optimized Cas9 CRISPR knockout library design

The continued development of high-dimensional CRISPR screen readouts, such as single-cell RNA sequencing and high-content imaging, necessitates compact libraries to enable functional interrogation at ...

biorxiv.org

What a great thread on budgeting for an academic lab!!

Adrian Liston@labliston.bsky.social · 11mo ago

🧵How to write and manage your first research budgets The point of funding is to convert it into quality research. A well-spent research budget should fund the idea it was raised on, plus revision experiments, plus preliminary data for the next grant. So you need to spend, while avoiding waste.

🧨Exciting new pre-print 🧨 Introducing ppmSeq - cost effective, scalable dual-strand 🧬🧬 sequencing. Scalability & ultra-low error in one! A game changer for somatic genome discovery science and cfDNA clinical apps. Check out thread for deets!

Alex@alexpellancheng.bsky.social · 12mo ago

Highly accurate sequencing OR high throughput? We refuse to choose. Introducing ppmSeq, a method built to deliver both. Our latest from the @landau.bsky.social lab with Ultima Genomics 👀👀👀 See ⬇️ for a primer on the next frontier of genomics www.biorxiv.org/content/10.1...

Karolinska is looking for 20 (!!) assistant professors and offering 6 year appointments with ~1M USD startup packages. ki.se/en/about-ki/...

Call for 20 Assistant Professor positions

Karolinska Institutet is a world-leading medical university with a long and proud history of ground-breaking research. We are now recruiting outstanding early-career researchers with particularly exce...

ki.se

It's my first #newPI roll call on BlueSky! Calling all new #cancer PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! 😃

Different modes of resistance to RAS inhibitors unveiled by dual Erk reporters that monitor erk activity in the nucleus and the cytoplasm. Cool new paper led by Markus Morkel and Oleksandra Aust www.science.org/doi/10.1126/...

Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer

A cell-sorting approach reveals distinct modes of cancer resistance to active-state RAS inhibitors.

science.org

We're very happy to invite you to the 𝟑𝐫𝐝 𝐘𝐨𝐮𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐅𝐫𝐞𝐧𝐜𝐡 𝐄𝐦𝐛𝐚𝐬𝐬𝐲 𝐢𝐧 𝐁𝐞𝐫𝐥𝐢𝐧 𝐨𝐧 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝟗 &𝟏𝟎. Visit our website ys2c.org for further information.

We have an attractive opening for a tenure-track professorship in Single-Cell Systems Biology. Excellent package and infrastructure at @uni-wuerzburg.de Institute of Systems Immunology. Great place to live and work in the heart of the franconian wine region! jobs.sciencecareers.org/job/673667/j...

junior professorship position (f/m/d) in Single-Cell Systems Biology - Würzburg (Stadt), Bayern (DE) job with Julius-Maximilians-University Würzburg - Faculty of Medicine | 673667

The Julius-Maximilians-University Würzburg, Faculty of Medicine is offering one junior professorship position (f/m/d) in Single-Cell Systems Biology.

jobs.sciencecareers.org

Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results:

nej.md

Excited to announce our preprint today @biorxivpreprint.bsky.social Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells: www.biorxiv.org/content/10.1...

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer...

biorxiv.org

Very happy that the first paper that started in our lab came out in @narjournal.bsky.social today ⭐🎊: BEscreen is a computational tool to design base editor sgRNA libraries for a broad range of use cases. It also allows for conveniently designing positive and negative controls and much more.

BEscreen: a versatile toolkit to design base editing libraries

academic.oup.com

Hello, Bluesky! ☀️ We fund frontier research in Europe—bold ideas, unexpected discoveries and science that shapes the future. So it’s only fitting we’ve landed here. Sorry for being late. Follow us for updates on ERC funding, research policy, and our grantees' discoveries.

End-of-the-year preprint & first 🧵 where the sky is blue! Ever wondered how a cancer driven by a single mutant oncogene becomes molecularly & cellularly heterogeneous? Why metastases share drivers w/primary tumors but are more aggressive?